HSA GN-21 R7 Adds Approval Gate for 6Aii/6Aiii Listing Changes

Singapore’s Health Sciences Authority (HSA) has issued GN-21 Revision 7, Guidance on Change Notification for Registered Medical Devices. The cover is dated August 2026 and marked Revision 7. The revision history records the effective text as GN-21: Revision 6.1 (01 Aug 2026). HSA’s guidance list labels the PDF “GN-21-R7 … (2026 Jul) PUB” and marks GN-21-R6 as archived on 31 July 2026. A separate Annex 2 is listed as August 2026.

GN-21 remains general guidance. Its preface says it is not a substitute for professional advice. Change Notification itself continues to be required under the Health Products (Medical Devices) Regulations 2010 for devices registered on the Singapore Medical Device Register (SMDR). Revision 7 does not rewrite that duty. It changes when two families of listing change may be implemented, and it adds a hard cap on concurrent applications.

This article covers only the Revision 7 delta. The 2025 Revision 6 story—expanded exemptions, MLMD flowchart 2.5, UDI change type 6E, and Class A remaining outside Change Notification—is already explained in Pure Global’s GN-21 Update 2025. Those R6 items remain in the current text unless noted below.

The listing-change rule that actually moved

Under Revision 6, Administrative Changes were split:

• changes to administrative documents and information submitted at registration required HSA approval before implementation in Singapore; but
• other changes to device particulars published on the public SMDR listing that fall under 6Aii/6Aiii of Flowchart 6A could be implemented immediately on receipt of the SHARE acknowledgement email.

Revision 7 removes that split. Administrative Changes now include both the registration-time administrative documents and the 6Aii/6Aiii public SMDR listing particulars. HSA’s R7 text says these require HSA’s approval prior to implementation of the change(s) in Singapore.

The change types themselves are not new. Annex 3 still describes:

• 6Aii as the limited additions of new devices of the same design: new models within the existing registered size range; pack-count changes of identical devices without breaching individual primary packaging; volume changes that do not affect specifications such as shelf life, stability, performance, and sterility; and repackaging of existing models in the same SMDR listing into different combinations without breaching individual primary packaging.
• 6Aiii as addition of a new device or software identifier with no change to the performance characteristics or specifications of the device.

What moved is implementation timing. A 6Aii or 6Aiii listing change that could go live on SHARE acknowledgement under R6 must now wait for approval before the modified listing is implemented in Singapore.

What still goes live on acknowledgement

Notification Changes are unchanged on this point. They may still be implemented immediately on the SHARE acknowledgement email. That category still includes:

• deletion or removal of device particulars published on the public SMDR listing; and
• other changes that are not Administrative, Technical, or Review, unless section 2.3 says no Change Notification is required.

Model deletions under 6B remain Notification. Incorrectly classified Notification applications can still be rejected on review, with further supply of the affected device prohibited until the change is approved in the correct category.

If a change is in the context of, or a consequence of, a reportable adverse event or field safety corrective action, implementation may proceed only after the FSCA or local AE has been reported to HSA’s Medical Devices Cluster. That AE/FSCA rule is not an R7 invention; it remains a condition on implementation timing.

The new two-application cap

Annex 2 to GN-21 R7 adds a question that was not in the R6 annex: whether there is an on-going Change Notification for listing(s) in the application.

The R7 note states that, at the point of submission, no more than two Change Notification applications may be active for the same listing. If any listing in a new application already has two active Change Notifications, the new application is rejected in its entirety. There is no refund of fees paid.

That cap is a portfolio-control rule, not a recategorisation of 6Aii/6Aiii. If a listing already has two active applications, a third filing is rejected in full and the fee is forfeited. GN-21 already said fees are non-refundable once an application is submitted via SHARE; withdrawal or rejection forfeits the charge. The two-CN note makes that consequence explicit for over-limit filings.

How this interacts with the existing 30-day Administrative TAT

Revision 7 does not publish a new turnaround time. Table 2 still gives 30 working days for Administrative Changes for Class B, C, and D, excluding stop-clock time for input requests. Review remains 45 working days for Class B. Technical remains 75 working days for Class C and 90 working days for Class D. The highest category in a bundled application still sets both TAT and fees.

Pure Global’s reading of the R6-to-R7 interaction is operational, not a new HSA TAT: 6Aii/6Aiii changes were already labelled Administrative in Flowchart 6A, but R6 allowed implementation on acknowledgement. R7 now makes the Administrative approval gate real for those listing changes. Teams should therefore plan supply of the modified 6Aii/6Aiii listing against the 30-working-day Administrative TAT, plus any stop-clock, rather than against the SHARE acknowledgement email. HSA did not say that every Administrative file will be decided on day 30.

What registrants should change in their procedures

Pure Global recommends a narrow procedure edit, not a full rewrite of GN-21:

1. Reclassify 6Aii/6Aiii implementation. Internal change-control SOPs and ERP release rules that treat SHARE acknowledgement as permission to supply the modified listing in Singapore are now wrong for those types.
2. Separate 6B deletions from 6Aii/6Aiii additions. Deleting published particulars can still follow the Notification acknowledgement path. Adding or recoding listing particulars under 6Aii/6Aiii cannot.
3. Count active CNs per SMDR listing before filing. If a listing already has two live applications, do not add a third. The whole new application will be rejected and the fee forfeited.
4. Bundle on purpose. Because TAT and fees follow the highest category, adding a 6Aii listing change to a Technical application still takes the Technical clock. Adding it as a stand-alone Administrative file now also means waiting for approval before implementation.
5. Leave the R6 machinery in place unless a later HSA text changes it: Class A still does not use Change Notification; 6E UDI submissions and flowchart 2.5 for MLMDs remain part of GN-21.

Read GN-21 Revision 7, the R7 Annex 2, and HSA’s Change Notification fees page. For the prior revision’s exemptions and MLMD/UDI content, see Singapore GN-21 Update 2025. Singapore market context is in the HSA glossary entry, Singapore market overview, and HSA medical device regulations.